skitahoe, yes this is true for now, because DCVax-L has not been commercially approved yet by the MHRA in the UK.
As a result, DCVax-L is currently only available under the Specials (Compassionate Use) program in the UK. As such, the accounting is not the same as a typical commercial sale transaction, because technically, DCVax-L is still an unapproved treatment in the UK.
This will change completely after the DCVax-L MA is approved by the MHRA. Then, 100% of all commercial sales of DCVax-L will flow through NWBio, and the accounting will reflect Gross Sales or Revenue on NWBio’s books and financial statements.
Then, IMO NWBio will pay Advent on a standard CDMO Cost Plus a percent basis, out of Gross Sales.
Bullish
Market Data 
Markets 
AI
